The Von Willebrand Disease (vWD) drugs in development market research report provides comprehensive information on the therapeutics under development for Von Willebrand Disease (vWD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Von Willebrand Disease (vWD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Von Willebrand Disease (vWD) and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Von Willebrand Disease (vWD) by 11 companies/universities/institutes. The top development phase for Von Willebrand Disease (vWD) is preclinical with four drugs in that stage. The Von Willebrand Disease (vWD) pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Von Willebrand Disease (vWD) pipeline products market are: Pfizer, Sanofi and Chugai Pharmaceutical.
The key targets in the Von Willebrand Disease (vWD) pipeline products market include Von Willebrand Factor (VWF), Coagulation Factor VIII (Antihemophilic Factor or AHF or Procoagulant Component or F8), and Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6).
The key mechanisms of action in the Von Willebrand Disease (vWD) pipeline product include Von Willebrand Factor (VWF) Replacement with four drugs in Pre-Registration. The Von Willebrand Disease (vWD) pipeline products include two routes of administration with the top ROA being Intravenous and five key molecule types in the Von Willebrand Disease (vWD) pipeline products market including Monoclonal Antibody, and Recombinant Protein.
Von Willebrand Disease (vWD) overview
Von Willebrand Disease (vWD) is a very common bleeding disorder that can be either inherited or acquired. It is caused by a deficiency of pro-von Willebrand factor which is a glycoprotein that plays a major role in hemostasis. This condition is classified as type-1, type-2, and acquired. People with this disease experience excess bleeding or a long duration for the bleeding to stop. It is usually diagnosed when a person experiences prolonged bleeding, recurrent bruising, and in females heavy or prolonged menstrual bleeding while undergoing dental extractions. Diagnosis is carried out by laboratory examinations like CBP, bleeding and clotting time, von Willebrand factor levels, and factor VIII activity. There is no specific treatment for von Willebrand’s condition, either symptomatic or measures to stop excess bleeding are considered. The most used medications are tranexamic acid for excess bleeding, desmopressin and von Willebrand factor concentrate.
For a complete picture of Von Willebrand Disease (vWD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
